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AWARENESS OF THE UNAWARE: ANOSOGNOSIA AS A COMORBIDITY IN MENTAL 
HEALTH CONDITIONS 
Integrative Literature Review 
The primary purpose of this integrative review of the literature is to describe healthcare 
provider’s recognition of anosognosia in individuals with comorbid mental health disorders, as a 
differentiating diagnosis needing preeminent early intervention. The secondary purpose is to 
examine how anosognosia influences outcomes in the population of individuals with severe 
mental illness. It is expected that early recognition by clinicians and implementation of 
additional interventions to address anosognosia as the most influential comorbidity of 
schizophrenia, will decrease exacerbations and improve treatment and patient outcomes.  
A literature review exploring clinician’s acknowledgement of anosognosia was performed using 
various databases. Search terms included: Anosognosia, Lack of Insight, Denial of Illness, and 
Schizophrenia. The data was conformed into tables and synthesized the relationships to identify 
consistent findings as well as gaps in the current literature. Initial review of the articles retrieved 
73 articles relevant to the topic and 18 articles that met inclusion criteria. The studies suggest 
that mental health conditions with anosognosia have increased rates of adverse outcomes. 
Anosognosia is a difficult disorder to identify. While many studies have explored the biological 
basis of anosognosia, the studies performed on safety with mental illness fail to acknowledge 
anosognosia as a co-morbid condition. Evaluation and clinical guidelines remain inconsistent 
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  INTRODUCTION 
Anosognosia, or the literal translation “Without Disease Knowledge”, has commonly 
been referred to as a lack of insight into one’s disease. Anosognosia has been recognized in a 
broad range of health conditions such as dementia, hemiplegia, and Huntington’s Disease, but is 
considered one of the cardinal clinical manifestations found in, 60-81% of all persons diagnosed 
with schizophrenia (World Health Organization, 2020). In individuals with schizophrenia, 
anosognosia is one of the most prevalent and influential attributes leading to adverse and 
inconsistent treatment outcomes of schizophrenia, including: Noncompliance to medication 
adherence, remission of psychological symptoms, impaired community function, risk of violence 
to self and others, and increased frequency of involuntary commitment to an acute mental health 
facility.  
In addition, the federal Healthcare Cost and Utilization Project, has found schizophrenia 
to be the third leading causes of hospital readmissions in the United States, only behind renal 
failure and ulcerative colitis (Fingar, K.R. et al., 2017). Anosognosia is a co-morbidity that 
carries heavy influence on the potential for positive outcomes in the treatment and management 
of schizophrenia, yet this complex construct has not been subjected to critical scrutiny or 
adequately addressed. Understanding the multifaceted phenomenon of anosognosia in the 
presence of related mental health conditions can improve the identification and treatment, and 









Psychiatric diagnoses are typically descriptive and are subject to scrutiny based on the 
clinical manifestations of the condition. There is currently no singular blood test or brain scan 
that can confidently diagnose a mental illness. Psychiatric mental health clinicians perform a 
series of exams and look to the DSM-V for diagnostic categories and dimensions as a pathway of 
assessment for underlying psychological conditions. Anosognosia is listed as an adjuvant clinical 
manifestations of schizophrenia in the DSM-V, however, at present time there is not a 
standardized diagnostic screening or plan of treatment for individuals with anosognosia as a 
comorbid condition with schizophrenia. This makes it exceedingly difficult to manage 
individuals that have disbelief in the accuracy of their diagnosis or the day-to-day consequence 
associated with their illness.  
The early detection of anosognosia and the pathological nature of the early stages of 
schizophrenia, are mainstay for reducing the duration of untreated psychosis. Reduction of the 
time an individual spends in a state of psychosis is exceptionally important because active 
psychosis is indicative of disease progression. Longer duration of untreated psychosis is 
associated with more severe symptoms when admitted to an acute care facility or mental health 
unit, poor prognosis, risk of violence, elevated risk for suicide, and more frequent relapses with 
involuntary commitment (Dell’Osso, Glick, Baldwin, & Altamura, 2013).  
At present time, reducing psychosis for the majority of individuals can only be achieved 
with consistent drug therapy adherence. The concept of insight into an individual’s mental health 
condition is the leading predictor of medication adherence, and primary reason for 
discontinuation of antipsychotic medication (Zhou, Rosenheck, Mohamed, 2017). When 
individuals do not have acceptance or acknowledgement of their illness, they are less likely to 
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seek out care or pay for drug therapy. Challenges in the care of a person with anosognosia and a 
combined mental health disorders occur when the individual’s preferences or beliefs, are at odds 
with the standard of care for their primary condition. Once correlations between anosognosia and 
poor treatment outcomes are established, clinician’s will be better prepared to implement 
additional interventions to guide treatment adherence and improved physiologic and 
psychological outcomes for this group of individuals.  
Anosognosia is a multifaceted phenomenon and planning for an appropriate treatment 
plan needs to take into account the individual's inability to recognize their illness, and failure to 
construct an adaptive narrative account of the challenges posed by having a psychiatric 
condition. An inability to reflect on the past and plan for the future makes the diagnosis of 
anosognosia in a mental health condition a key factor when determining treatment and drug 
therapy. Poor insight can directly influence difficulty in making sense of positive and negative 
clinical manifestations of psychiatric conditions (Osatuke, Ciesla, Kasckow, Zisook & 
Mohamed, 2008). For example, individuals with schizophrenia may have temporary delusions, 
however, individuals with schizophrenia and anosognosia are more likely to preserve positive 
symptoms as their reality, which can influence all decisions thereafter based off of fabricated 
knowledge.  
When determining an individual’s decisional capacity, three primary domains emerge as 
the most important and predictive results to show functional competency and vulnerability 
enhancement. The three primary domains affected by anosognosia are as follows: 1) Executive 
functioning, memory, and insight, 2) Decisional capability for health care treatment and other 
daily decisions involved in the comprehension of the nature of the information about the 
condition, and 3) The understanding of application to one’s own condition, and the ability to 
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process and critically understand the information provided (Jeste, Depp, & Palmer, 2006). People 
who suffer from anosognosia will have an impaired ability to make well-informed decisions 
about health care and are more likely to suffer poor outcomes such as financial loss and 
increased risk for exacerbations of their mental health condition.  
With contradicting evidence and a complex history, anosognosia is currently measured 
and treated as a multifactorial anomaly that stems from psychological, neuropsychological, and 
organic components. Increased admissions to acute care facilities, crisis stabilization units, and 
correctional facilities can result from lack of recognition for this co-morbidity, resulting in under 


















The primary purpose of this integrative review of the literature is to examine how 
anosognosia influences outcomes in the population of individuals with severe mental illness. The 
secondary purpose is to describe healthcare provider’s recognition of anosognosia in individuals 
with comorbid mental health disorders, as a differentiating diagnosis needing preeminent early 
intervention.  It is expected that early recognition by clinicians and implementation of additional 
interventions to address anosognosia as the most influential comorbidity of schizophrenia, will 



















The investigation into anosognosia clinically requires a carefully operationalized, 
working knowledge definition, as well as a systematic method of measuring and quantifying the 
level of insight one has into their illness. While this remains a challenge, mental health clinicians 
have defined the concept of “insight” as an individual’s ability to understand the conceptual 
elements as the following:  Awareness to having an illness; Recognizing the signs and symptoms 
while accrediting consequences and deficit to the illness; and, The ability to appreciate and 
understand the need for treatment. “Insight,” is thus recognizable as a multifactorial construct 
measured on a continuum, rather than an “all or none” phenomenon (David, 1990).  
Recognition of “anosognosia,” as its own terminology is not a clearly defined concept 
across the mental health continuum. Little distinction has been made between anosognosia, lack 
of insight, and denial of illness, as these terms have often been used interchangeably to describe 
the neurological and psychological phenomena of anosognosia. The term, ’denial’, is 
distinguished as a reflection of a healthy perpetual defense mechanism, rather than a pathological 
avoidance of reality. The consistency and magnitude to which denial is attributed to healthy 
functioning in an individual, suggests that it is a psychological base of coping (Haan & Harder, 
1992). Individuals experiencing denial have information of illness cognitively and consciously 
available to them, but dismiss it in an attempt to protect against distress and preserve emotional 
wellbeing. By contrast, those with anosognosia do not have the information of illness available to 
them to contemplate over. More than denial, the term ‘anosognosia’ is defined as a deficit of 
self-awareness related to unawareness of neurological defects regardless of compelling evidence, 
adjoined with the use of confabulation to explain any threats indicating illness. It is therefore 
pertinent to acknowledge that these individuals are unable to fathom their illness themselves 
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when being screened for psychiatric illness. Understanding the dissimilarity between 
anosognosia and denial will not only aid in the standardization of terminology and accuracy for 
future research, but will also help mental health practitioners recognize the gravity of this 
diagnosis, rather than seeing it as a symptom of a larger disease.  
 
Assessment of Anosognosia 
In an attempt to quantify and measure such a complex construct, several instruments 
currently exist to measure the level of insight one has into their illness. Among these various 
tools, the Scale to Assess Unawareness into Mental Disorder (SUMD) is one of the most widely 
used instruments taking into account the wide psychometric properties of the illness. Presented 
as an interview derived from Amador’s complex model of insight, the SUMD distinguishes the 
processes of awareness and attribution through a 74 piece questionnaire assessing: Awareness of 
having a mental disorder, recognition of signs and symptoms and explanations of the cause of 
these signs and symptoms (Amador et. Al, 1994). Consider question 2 on the SUMD, “awareness 
of the achieved effects of medication.” This questions the individual’s beliefs regarding the 
effects of medication and explicitly associates medication compliance with one’s level of insight. 
Medication compliance is thus built in as a beneficial assumption for patients, into the very 
instrument used by clinicians to assess for anosognosia. Unfortunately, although the SUMD has 
proven to be the most reliable tool when assessing insight, the extensive length of this test makes 
it commonly used solely in studies and not in clinical settings.  
In addition to the SUMD, there are several self-administered validation tools that are 
present among extensive literature such as the Beck Cognitive Insight Scale (BCIS). This exam 
measures the extent to which an individual recognizes their illness and need for treatment by 
 
 9 
evaluating patients’ self-reflectiveness and self-certainty of their experiences. One’s self-
reflectiveness includes items measuring the ability to have objectivity and openness to feedback, 
and the latter measures one’s certainty about their beliefs and judgment (Beck, A.T, 2004). These 
subscales are useful when determining an individual's willingness and capacity to entertain 
corrective feedback about delusional beliefs and thinking. The overall estimate of the composite 
cognitive insight index score is then measured taking the score of self-certainty and subtracting it 
from the self-reflectiveness subscale. This index was found to significantly correlate with the 
Awareness of Having a Mental Disorder item on the SUMD (Riggs, S., Grant, P., Perivoliotis, 
D., & Beck, A.T., 2012). 
While these are the current tools that psychiatric professionals use to determine the extent 
of insight an individual has insight into their disease, the measurement tools are not purposefully 
designed to thoroughly evaluate the multidimensional nature of the clinical phenomenon of 
anosognosia. Development of a standardized tool to diagnose and measure anosognosia would 
not only aid in clinicians identification of these individuals, but would also allow for reliability 
and standardization of research results.  
 
Theory of Organic Abnormalities as a Factor of Anosognosia 
Although still in its clinical incipiency, anosognosia was originally a term coined by 
renowned psychologist Joseph Babinski, with regards to a lack of insight into specifically, left 
hemiplegia. The concept of anosognosia reflects on the idea that focal lesions and diffuse brain 
damage caused individuals with left hemiplegia to have unawareness of the paralysis that 
affected them. As expressed by Xavier Amador, individuals exhibiting poor insight into 
schizophrenia remarkably parallel the same characteristics expressed by individuals with 
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neurological disorders. As seen in 10-18% of stroke victims with hemiparesis, these individuals 
present with a severe lack of awareness into their illness, deny illness despite conflicting 
evidence, use confabulations in order to explain observations made by others, and have a 
compulsion to prove their self-concept (Amador & Paul-Odouard, 2000). Since the acceptance of 
this parallelism, many studies have been conducted in an attempt to examine the areas of the 
brain responsible for causing impairment of insight.  
Theories have often framed schizophrenia as disorder resulting from a disruption in 
neural connectivity leading to impaired communication between areas of the brain. The 
advancement of neuroimaging techniques have provided researchers with the ability to see an 
unparalleled window into the changes of the brain seen in schizophrenia that are associated with 
structural abnormalities including neutrophil loss and reduced gray matter volumes in the 
prefrontal cortex. The diagnosis of schizophrenia is now accepted as a hypo-functionality of the 
prefrontal cortex, which is critically responsible for short-term memory, auditory processing, 
episodic memory and decision-making. Anosognosia, as a complex construct of insight and 
recognition, is also mediated by brain regions at a higher hierarchical level of thought 
processing. One study performed by Shad, Muddasani, and Keshavan, measured specific 
prefrontal sub-regions in individuals with schizophrenia, using voxel-based morphometry, an 
MRI technique used to investigate focal differences in brain anatomy. In this study, researchers 
utilized the SUMD (Scale to Assess Unawareness in Mental Disorder) assessment tool to 
quantify the insight function in 14 subjects, and compare their level of insight to the dorsolateral 
and orbitofrontal regions in the prefrontal cortex. The findings from this study resulted in an 
inverse relationship between the volume of the dorsolateral region and awareness of symptoms 
(Shad et. Al, 2006). The dorsolateral region of the brain being most commonly associated with 
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executive functions including: The working memory, selective attention, and self-
monitoring. The results from this study are further validated from a study performed in the 
Netherlands asking 47 individuals with schizophrenia and 21 normal controls, to think about 
themselves while being assessed by a functional MRI. The individuals with anosognosia showed 
significantly lower activation in several areas of the brain as compared to the individuals that had 
high scores of insight when assessed using the Beck Cognitive Insight Scale.  
It would be ideal to merit the same neurologic disturbances for both psychiatric and 
neurological individuals causing the underlying the problem of lack of insight. However, since 
the biological basis of neural activity and thought processing areas of the brain are not fully 
understood for individuals with anosognosia as a comorbid condition with other mental health 
disorders, treatment for mental health disorders is often reactive rather than proactive, leading to 













The development of the operationalized definition of anosognosia in conjunction with 
new clinical measurement tools for insight, have allowed clinicians to better recognize that 
persons with severe mental illness are a heterogeneous group. A large percentage of individuals 
with serious mental illnesses are able to recognize their condition, and are willing to participate 
in treatment. These are the individuals that show fewer problems with substance abuse, violence, 
and have the most potential for recovery. Alternatively, individuals that have anosognosia, have 
presented throughout literature with poor treatment compliance, increased risks for violence and 
increased risks for suicide. With the developing ability to recognize individuals with 
anosognosia, additional steps should be taken to implement a standardized diagnostic tool, 
classify anosognosia as a subtype diagnosis, implement early interventions, and treatments to 













For this thesis, research articles were identified, systematically analyzed, and synthesized 
in order to gain a better understanding of the current literature on anosognosia in the presence of 
co-morbid mental health conditions, the populations healthcare needs, and effect on individual 
treatment outcomes and admissions to acute care facilities or crisis stabilizations units. Databases 
that were used to search for articles included Cumulative Index to Nursing and Allied Health 
Literature (CINAHL), Educational Resources Information Center (ERIC), Elton B. Stephens Co. 
Host (Ebsco Host), Medical Literature On-line (Medline), and Psychological Information 
Database (PsychINFO). Searches used a combination of the following terms: anosognosia, lack 
of insight, denial of illness, treatment adherence, violence, suicide, hospitalization, and 
schizophrenia. Inclusion criteria were peer-reviewed articles and publications written in the 
English language that were available from 2000-2020. While the focus of this study is on 
practices in the United States, international articles written in the English language will be 
included. Exclusion criteria included articles published in a language other than English and 
dates outside of the specified publication date, articles without evidence of anosognosia as a 
significant comorbidity of an existing mental health disorder, and lack of evidentiary support for 
admission to a facility directly due to anosognosia.   
Each article will be evaluated and critiqued for relevance to the topic and its application 
in individuals with anosognosia and clinical practice. Subsequently, all of the articles will be 
synthesized to identify consistent findings as well as the gaps in the current literature. An 
evidence table will be developed to highlight findings for each article and will be included in the 
review for this thesis.  
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This literature search yielded 3,902 results for the key terms “anosognosia,” “lack of 
insight” and “schizophrenia.” After exclusion criteria were applied, 1,746 results articles were 
eliminated. The remaining 2,156 articles were reduced again to include only the key terms 
“anosognosia” and “schizophrenia” and this yielded 209 results. Another pooling of terms was 
used for “anosognosia,” and “treatment” or “adherence” or “suicide” or “violence” and 
“schizophrenia” yielding 73 results when exclusion criteria were applied. The remaining articles 
will be reviewed for relevance and additional studies from references were included in the 

















Disparities in Outcomes and Need for Early Intervention 
The analysis of the literature review revealed a common health-related theme among 
individuals that have anosognosia, specifically, the greater potential for negative outcomes due 
lack of treatment compliance. Individuals with severe mental disorders are at heightened risk for 
hospitalizations, risk of violence to self or others, and suicide, either due to anosognosia or poor 
treatment compliance. Each of these potential negative outcomes are examined in greater detail 
in the next section of this paper.  
Treatment Adherence and Insight 
 Among the research included in the table of evidence, six of the studies are focused 
around the correlation between an individual’s level of insight, and their compliance to 
prescribed treatment plans. All of these studies are similar in that they assess individuals that 
have a DSM diagnosis of schizophrenia. Three of the studies: (Kamali, M., Kelly, B.D., Clarke, 
M., Browne, S., Gervin, M., Kinsella, A., Lane, A., Larkin, C., O'Callaghan, E. (2006) and 
(Coldham EL, Addington J, Addington D. 2002) and (Novak-Grubic, V. & Tavcar, R. 
(2002) assessed the correlates of treatment adherence in patients that were admitted into an acute 
care facility during their first episode of psychosis. The sample subjects of these studies were 
assessed at baseline and then followed up six months, to one year later. Data collected at follow 
up appointments were different for each of these three studies, however, the Positive and 
Negative Symptom Severity scale (PANSS) was consistently used in order to measure the 
subject’s levels of insight. (Kamali et. al, 2006) found that of the (N=60) individuals, one third 
exhibited poor insight at baseline and were found to be non-adherent to medication within the 
first 6 months of discharge. This study yielded similar results to (Coldham et. al, 2002), which 
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found non-adherent individuals to have significantly poorer insight at both assessments. Lastly, 
the study conducted by (Novak-Grubic et. al., 2002) aimed to assess the predictors of 
noncompliance and outcomes for male individuals following their first episode of psychosis. 
This study concluded that lack of insight was one of the leading predictors for non-compliance to 
treatment. In addition, outcomes for the treatment compliant group were notably favorable with 
relapse rates significantly lower than the non-adherent group. These results should be used to 
establish a strategy that emphasizes special attention paid to compliance-promoting 
interventions, in order to decrease readmissions to acute care facilities.  
 In addition to these studies, Hassan, A.E., Elnabawy, A.,  Eldeeb, M., & Essa, A. (2019), 
and Mohamed, S., Rosenheck, R., McEvoy, J., Swartz, M., Stroup, S., Lieberman, J.A. (2009), 
further validate poor insight as the greatest predictor for lack of treatment adherence with data 
collected from a combined sample size of (N=421). The study findings by Mohamed et. al, 
(2009) went further to suggest that higher levels of insight are associated with lower symptom 
severity, and better community function. Contrariwise, these results can infer that the overall 
course of illness is highly influenced by the presence of anosognosia as a co-morbidity. Lastly, 
Tessier, A., Boyer, L., Husky, M., Baylé, F., Llorca, P., & Misdrahi, D. (2017), used a cross-
sectional study to asses the relationships between individual’s self-reported medication 
adherence, insight, and therapeutic alliances, with several other measures. Results showed that 
treatment adherence can be enhanced by increasing one’s level of insight through therapeutic 
alliance with a psychiatrist. Thus, continuous follow-ups and consistency with office visits would 




 Overall, the studies focusing on outcomes following first episode of psychosis, can 
concluded that identifying the subgroup of individuals with anosognosia can predict poor 
treatment adherence behaviors in the future. The studies that were analyzed for this review 
reinforce a need for specialized continuous interventions for the subtype of individuals with 
anosognosia in order to promote compliance.  
 
Negative Outcomes 
The research discussed has substantial evidence to demonstrate anosognosia as a pivotal 
comorbidity affecting patient’s non-adherence to treatment. However, it is crucial to recognize 
the importance of remaining adherent to treatment, as adherence is the leading predictor for 
determining individuals’ with mental illness’ outcomes. Four studies from the table of evidence 
investigate correlations to unwanted hospitalization for individuals with schizophrenia. In a 
retrospective study conducted by Weiden, Kozma, Grogg, and Locklear (2004), (N=4,325) 
individuals were assessed for adherence to antipsychotic medications in relation to unwanted 
admissions to psychiatric facilities. Their results yielded that individuals reporting adherence of 
MPR (medication possession ratio) greater than 70% are less likely to be hospitalized, as 
compared with noncompliant individuals. Overall, the risk for hospitalization increased from an 
Odds Ratio of 2.81 (if non-compliant for only eleven days) to 3.96 times more likely for 
hospitalization, if there is a gap in medication greater than 30 days. These results suggest that the 
longer an individual goes un-medicated, the more presumable it is the individual will be 
hospitalized. These results are further validated by a study conducted by Morken, Widen, and 
Grawe (2008), which assess the outcomes associated with treatment adherence. Results from this 
study show that non-adherence to either oral or depot antipsychotic medication, are associated 
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with an Odds Ratio (OR) of 10.27 for having a psychotic relapse, and a 4.00 OR for readmission 
to a hospital (Morken et al., 2008). Both Morken, et. al, and Weiden, et. al, conclude there is 
nearly a four-fold chance of using hospital services if the individual is non-adherent to 
medication.  
Proper ability for clinicians to identify anosognosia as comorbidity and further 
interventions to increase treatment adherence are paramount for potential beneficial impacts on 
the mental health and criminal justice delivery systems. Ascher-Svanum, Faries, Zhu, Ernst, 
Swartz, and Swanson (2006), prospectively examined the relationships between adherence with 
antipsychotic medications and functional outcomes among (N=1,906) individuals with a DSMIV 
diagnosis of schizophrenia. The outcomes measured included: Psychiatric hospitalizations, use of 
emergency psychiatric services, arrests, violence, victimizations, poorer mental functioning, 
poorer life satisfaction, greater substance use, and more alcohol-related problems. Using 
interviews in six month intervals for three years, Ascher-Syanum et. al’s findings highlighted 
that non-adherence in the first year significantly predicted poorer functional outcomes in the 
following two years.  
From these results, it can loosely be assumed that early interventions would significantly 
influence the potential for positive outcomes in the individuals’ future years. Interventions to 
ensure compliance in the early stages following discharge can decrease unwanted admission to 
facilities, and decrease periods of time spent in psychosis. Longer durations of untreated 
psychosis is associated with more severe symptoms when admitted to an acute care facility or 
mental health unit, poor prognosis, risk of violence, elevated risk for suicide, and more frequent 




Insight and Violence 
Another common theme that emerged in the research was the incidences of violence 
among persons with anosognosia in their severe and persistent mental illness. It is important to 
note that most individuals with serious mental illness are not dangerous and more likely will be 
victims of perpetrators of violent acts. Nonetheless, individuals with anosognosia are at 
heightened risk for violent behavior when their symptoms remain untreated, especially with 
psychosis and paranoia (Treatment Advocacy Center, 2016). Four studies from the table of 
evidence examine schizophrenia and its correlation to violence as an outcome. The leading 
factors contributing to violent acts being: Non-adherence to medication, as well as presence of 
anosognosia. Ascher-Svanum et al. found within the measured functional outcomes, non-
adherent patients were more than twice (10.8% versus 4.8%; p < 0.001) as likely to engage in 
violent activities and be arrested, than the control sample of adherent patients (Ascher-Svanum 
et. al, 2006). Similar measures were used by Elbogen, Van Dorn, Swanson, Swartz, and 
Monahan (2006), who sampled (N=1,011) outpatients from five US cities, assessing attitude 
towards medication adherence and physically assaultive behavior, over a six month time span. 
The results were cross-examined using logistic regression for correlations between violence and 
attitude towards perceived treatment need. Those who became physically assaultive were 
significantly more likely to be non-adherent to treatment (p<0.001), more severely ill, and 
abusing substances. The findings from this study provide empirical support for the assertion that 
adherence to medications is associated with reduced violence in patients with severe mental 
disorders.  
Upon closer examination of violent acts committed by individuals with severe mental 
illness, two studies from the table of evidence examine the extent to which anosognosia is a 
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factor. Lincoln and Hodgins (2008), examined (N=209) individuals that had previously been 
admitted to a hospital, on average, 8.5 times. A chi square test was used to test the association 
between the PANSS-insight ratings and history of physically aggressive behavior, over the last 
two years. Results showed that significantly more patients with low or no insight, when 
compared with those with good insight, behaved aggressively in the second and third follow-up 
periods (Lincoln, et. al, 2008). Consistent with these results, Buckley, Hrouda, Friedman, 
Noffsinger, Resnick, and Camlin-Shingler (2004) also found that the violent individuals from 
their sample group had marked deficits in insight (71% scoring 4 [moderate deficit] or more, and 
12.5% scoring 7 on the PNSS, with significantly greater deficits than nonviolent patients on both 
the PNSS and SUMD) (Buckley et. al, 2004). Identification of anosognosia in individuals with 
schizophrenia would therefore enhance clinician’s violence risk assessment in psychiatric 
practice settings.  
 
Suicide  
As the second leading cause of death in Americans aged 15-24 years old, suicide is 
becoming a strong vector of concern. Not coincidentally this is the age group in which most 
young people leave for college, join the military, and experience a first episode of major mental 
illness. Of the suicides reported to the CDC in 2018, more than 54% of them did not have a 
known mental health condition. As a preventbale cause of death, addressing the known risk 
factors can help decrease the risk for suicide among individuals with serious mental illness. 
These influential factors include: Depressive symptoms, substance abuse, awareness of illness, 
and a history of violent behavior (Treatment Advocacy Center, 2016).  
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Three studies from the table of evidence examine suicide as a negative outcome for 
individuals with a potential diagnosis of anosognosia in their mental illness. Findings from a 
study conducted by Verma, Srivastava, Singh, Bhatia, and Deshpande (2016), (N=175) suggest 
that there is a triangular relationship between individuals with good insight, better executive 
functioning, and suicide attempts at some point during the illness (Verma, et. al, 2016). While 
this study suggests that individuals who lack anosognosia are more likely to commit suicide, this 
study fails to incorporate the level of treatment compliance within the sample. As results from 
the studies in the table of evidence have shown, treatment adherence maintains a huge influence 
on outcomes. For example, a suicide and mental illness study based in Kentucky found that out 
of (N=28) individuals only 2 persons who had killed themselves had evidence of their 
antipsychotic medications in their blood. Therefore, 93% of the sample was left untreated or had 
not been adherent with their medications (Shields, Hunsaker, & Hunsaker, 2007).  
Moreover, another study taking into account the level of treatment adherence was 
conducted by Barrett, Mork, Færden, Nesvåg, Agartz, Andreassen, and Melle, (2015). This study 
investigated the relationship between suicidality and insight, in individuals that had been 
adherent to treatment for more than 52 weeks following their first episode of psychosis. Barrett 
et. al, yielded results exhibiting patients who gained insight over their first year in treatment, 
were, to a lesser degree, suicidal at one year follow-up. (Barrett et. al., 2015). Overall, the status 







DISCUSSION AND KNOWLEDGE GAPS 
The literature review supports that there is an imperative need for clinicians to recognize 
and treat anosognosia as a unique co-morbidity in mental illness needing additional interventions 
following clinical guidelines. An overarching finding among studies is that individuals with 
anosognosia are particularly at risk for lack of treatment adherence. Without compliance to 
medication, these individuals will experience increased potential for negative outcomes, such as: 
Unwanted admissions to psychiatric facilities, violence, and risks for suicide. The literature 
synthesis highlights the need for a standardized diagnostic tool, early intervention, as well as the 
need for a contingency plan when planning treatment.  
Of the literature that has been reviewed for this study, there is a lack of continuity when it 
comes to evaluating the sample populations for ansogonosia, and the methods used to reevaluate 
these individuals. While the use of the Positive and Negative Symptom Severity Scale (PANSS), 
was the predominate tool used, only one item out of thirty in the PANSS is used to assess the 
level of insight. As a tool used for measuring sensitivity to treatment changes, this tool should be 
used for assessing overall responsiveness to medications, rather than assessing for, and 
measuring changes in level of insight for individuals with anosognosia. The use of the PANSS 
tool, rather than tools used specifically for measuring insight, such as the Scale to Assess 
Unawareness in Mental Disorder (SUMD), or Beck Cognitive Insight Scale, can have 
implications for the criteria and methods used in samples of future studies. Standardization of the 
tool used to assess for anosognosia in individuals with schizophrenia allows for validity and 
reliability when comparing research.  
Throughout the literature, there was consistently a gap in treatment behavior of the 
samples of individuals with anosognosia. In numerous studies the sample population was being 
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monitored for adherence to medications, alternatively, some studies failed to monitor whether or 
not the population was being adherent to medication regimes. This difference in the sample’s 
behavior can lead to concomitants in individual outcomes. Collectively, samples should mirror 
behavior in treatment adherence, in order to produce standardized results for measuring 
outcomes in individuals with anosognosia.  
Another issue alluded in the literature is the limited number of studies that differentiate 
treatments plans for individuals with anosognosia, versus the typical treatment for someone with 
schizophrenia. Clinicians should make a distinction between diagnoses, as the subtype of 
schizophrenia with anosognosia, should portend non-compliance as the biggest outcome 
predictor. While much of the current research has been into reactive measures to increase 
treatment compliance, future research should be proactive in testing interventions increase 
compliance in these individuals with anosognosia. With enough research to assume individuals 
with anosognosia are more likely to have poor compliance, investigation into structured 














While there exists several tools for measuring one’s insight into their illness, 
standardization of a diagnostic tool to test for anosognosia would allow clinicians to better 
identify this co-morbidity in individuals with severe mental illness. In addition to improving 
clinicians’ recognition of this disorder, standardization would also allow for greater reliability 
and validity of research into optimal treatment plans for individuals with anosognosia. Current 
research into the use of an abbreviated version of the Scale to Assess Unawareness in Mental 
Disorder (SUMD) shows promising results as a dependable tool to be used in clinical practice 
when identifying anosognosia as a co-morbidity. As a recognized diagnosis with heavy influence 
on re-hospitalization, violence, and suicide, clinicians should reclassify patients with 
anosognosia into a high-risk category following evaluation.  
Unsurprisingly, lack of fully developed clinical guidelines for anosognosia as a 
comorbidity in mental illness, can be rationalized by the absence of a standardized diagnostic 
tool. Currently, clinical practice guidelines exist within medicine to serve as a framework for 
clinical decisions and support the best evidence based practices for improved patient outcomes. 
The American Psychiatric Association failed to acknowledge anosognosia as a comorbid 
condition in the Practice Guideline (December 2019) for Treatment of Patients with 
Schizophrenia as well as the Practice Guideline (August 2015) for Psychiatric Evaluation 
(American Psychiatric Association, 2020). Currently, Treatment Guidelines from the American 
Psychiatric Association project to be updated in the Summer of 2020. This update should include 
anosognosia as a potential comorbidity, and should be included in the initial evaluation of all 
individuals with a potential diagnosis of schizophrenia. The required screening for anosognosia 
during the first evaluation would require the clinician to subtype the diagnosis of schizophrenia 
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as “with/without anosognosia”. Such a requirement would drastically change treatment plans and 
hospital discharge plans, allowing for advanced planning and tailored treatment regimes for these 
individuals.  
As a high-risk category of individuals, additional measures should be taken to ensure that 
they are compliant to medication and treatment regimes. In our current health care system in 
America medical decisions are based off of liberty and autonomy. Just as all Americans, people 
living with mental health conditions have the right to make decisions about their lives, including 
their medical treatments. In a system that governs psychiatric patients through their freedom of 
will, the logic of anosognosia introduces the intractable dilemma: Can a person make an 
informed choice to refuse treatment, if the symptoms of the illness impair awareness of the 
illness itself? This durable link between psychiatry and the law must align with a common 
understanding of anosognosia and it’s relation to compliance behaviors. 
It is estimated that schizophrenia only affects 1.1% of the population in the United States 
of America. Despite this relatively low prevalence, schizophrenia is associated with substantial 
economic burden in the United States. Tax payer’s estimated economic costs to manage 
individuals with schizophrenia totaled to over $155.7 billion in 2013 (Cloutier, et. al, 2016). This 
total equivalates an average excess annual cost of over $44,733 per person with schizophrenia. In 
comparison, at a cost of $327 billion dollars annually to manage an estimated 88 million adults 
with pre-diabetes, diabetes has become the most expensive chronic disease in the U.S (American 
Diabetes Association, 2020). Nevertheless, the overall economic burden to manage an individual 
with schizophrenia is more than twice the cost to manage an individual with diabetes annually. 
With high expenses, investigations into the driving forces of expenses for individuals with 
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Schizophrenia, are needed in order to target areas of focus for treating these individuals more 
effectively.  
Since it is not uncommon that individuals with anosognosia will resist treatment, a 
structured environment with monitoring is needed to ensure compliance to medications. Of the 
studies that have tested, certain interventions such as Mandatory Outpatient Treatment is noted to 
have positive effects on individuals with anosognosia that have resisted treatment. Up to 75% of 
individuals with this court order have said MOT has helped them regain control of their lives, 
81% have said that MOT helped them get and stay well, and 90% of individuals have said MOT 
has made them more likely to keep appointments and take medication (Treatment Advocacy 
Center, 2020). With repeated results of improvement with adherence and positive outcomes, 
MOT should become a guideline for treating individuals with anosognosia.  
Anosognosia is a common comorbidity in schizophrenia and should be evaluated by all 
clinicians. With the ability to promote better patient outcomes through early recognition of this 
comorbidity, the inclusion of anosognosia should be included into the American Psychiatric 
Association’s clinical guidelines and evaluations for patients with schizophrenia. It can be 
loosely correlated that early recognition of this disorder will allow for reduced hospitalizations, 
increased treatment adherence, and decreased risks of violence to self and others. Research into 
the best proactive treatment measures is increasingly important for potentially good outcomes, 
and should be the focus of future research. Successful efforts should permit early disease 
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